Friday, August 26, 2016

Cellect completes NASDAQ IPO

Cellect completes NASDAQ IPO

August 3, 2016 by · Leave a Comment 

Tweet Cellect Biotechnology (NASDAQ:APOP; TASE:CLBD) priced an initial public offering in the U.S. of 1,292,308 American Depository Shares (ADSs) and warrants to purchase up to 969,231 ADSs. Each ADS, representing 20 ordinary shares of the company, and each warrant to purchase ADSs were offered at a combined price of $6.50, which equated to a 13% discount […]

Rodman starts Catalyst Biosciences at buy

Rodman starts Catalyst Biosciences at buy

June 30, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw initiated coverage of Catalyst Biosciences (NASDAQ:CLIO) with a “buy” rating and a 12-month price target of $3.50. The stock closed at $1.25 on Wednesday. Using its proprietary protease platform, Catalyst Biosciences is advancing its lead hemostasis programs for hemophilia A and B, as well as its anti- complement programs, which could […]

Rodman starts OpGen at buy

Rodman starts OpGen at buy

June 29, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has initiated coverage of OpGen (NASDAQ:OPGN) with a “buy” rating and 12-month price target of $2.50. The stock closed at $1.56 on Tuesday. “In our view, the company’s QuickFISH assays, the latest generation of its fluorescence in situ hybridization (FISH) platform, are differentiated from competitors in that they utilize the unique […]

Rodman starts NeuroMetrix at buy

Rodman starts NeuroMetrix at buy

June 29, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has initiated coverage of NeuroMetrix (NASDAQ:NURO) with a “buy” rating and 12-month price target of $4.50. The stock closed at $1.74 on Tuesday. NeuroMetrix is a commercial-stage medical device company aimed at management of chronic intractable pain due to conditions such as diabetes, fibromyalgia and arthritis. “In our view, the company’s […]

Rodman starts Presbia at buy

Rodman starts Presbia at buy

May 11, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has initiated coverage of Presbia PLC (NASDAQ:LENS) with the “buy” rating and 18-month price target of $14. The stock closed at $3.90 on Tuesday. Presbia has a novel corneal inlay product, the Flexivue Microlens, aimed at treating presbyopia, or nearsightedness. “From our perspective, Presbia is an unsung company with an intriguingly […]

Rodman starts LabStyle Innovations at buy

Rodman starts LabStyle Innovations at buy

May 9, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has initiated coverage of LabStyle Innovations (NASDAQ:DRIO) with a “buy” rating and $12 price target. The stock closed at $5.40 on Friday. LabStyle is an emerging digital health company focused on the monitoring and management of diabetes. Analyst Raghuram Selvaraju writes that the company has developed an integrated system to enable […]

TearLab prices $17.3-million registered public offering

TearLab prices $17.3-million registered public offering

May 4, 2016 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has priced a public offering of common stock to raised gross proceeds of approximately $17.3-million to close on May 9. The offering was priced at 75 cents a share of common stock, or common stock equivalent, with each share of common stock coupled with a warrant to purchase one-half of one […]

Rodman starts Bio-Path at buy

Rodman starts Bio-Path at buy

April 19, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has launched coverage of Bio-Path Holdings (NASDAQ:BPTH) with a “buy” rating and a 12-month price target of $5. The stock closed at $2.76 on Monday. “In our view, Bio-Path’s unique liposomal delivery of antisense DNA has the potential to significantly improve treatment outcomes in elderly patients (≥60 years) with acute myeloid […]

Rodman assumes coverage of NephroGenex at neutral

Rodman assumes coverage of NephroGenex at neutral

April 15, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw analyst Raghuram Selvaraju has assumed coverage of NephroGenex (NASDAQ:NRX) with a “neutral” rating and without a price target. The stock was quoted at 40 cents Friday afternoon. The board of NephroGenex decided in late February 2016 to pause the oral Pyridorin pivotal program in diabetic nephropathy, to effect a restructuring of […]

Rodman assumes coverage of Semler Scientific at buy

Rodman assumes coverage of Semler Scientific at buy

April 15, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw analyst Raghuram Selvaraju has assumed coverage of Semler Scientific (NASDAQ:SMLR) with a “buy” rating and $8 price target. The stock was quoted at $2.05 Friday afternoon. Semler’s 2015 revenue of $7-million represented growth of 93% over the 2014 revenue of $3.6-million. “In our view, the solid revenue growth demonstrates the continual […]

Next Page »

Email Newsletters with Constant Contact
Google+